Working under the supervision of Professor Shi Cao in the Department of Systems Design Engineering, Shefali is using her computer science background to help develop an innovative face recognition app for Google Glass — a type of “wearable technology” — like glasses with an optical head-mounted display.
Hailing from the Birla Institute of Technology and Science, in Pilani, India, Shefali says she is thrilled to take part in research involving Google Glass, calling her project an “amazing opportunity to have hands-on experience with today’s technology.”
Working under the supervision of Dr. Janet Light and PhD student Ali Reza Manashty at the University of New Brunswick Saint John, Umang is helping to develop the components of a comprehensive remote healthcare system designed for senior citizens and physically disabled individuals.
During the summer of 2014, researchers at the University of Waterloo’s School of Pharmacy were looking into whether a group of drugs called selective serotonin re-uptake inhibitors (SSRIs) — normally used as anti-depressants — could be used to treat Alzheimer's.
The project started when Michael Gray was researching earthquake-proofing techniques as a postdoctoral fellow at the University of Toronto’s Department of Civil Engineering. Michael had developed a prototype connector device with one end that could grip part of a building’s frame between a pair of comb-like pincers, while the other end was welded to a brace.
Richard is an alumnus of the University of Ottawa's SUNLAB.
Mitacs gratefully acknowledges Western Economic Diversification, the Atlantic Canada Opportunities Agency and the governments of Alberta, British Columbia, Manitoba, and New Brunswick for their support of Mitacs Elevate. In addition, select Elevate fellows are supported through Mitacs Accelerate and its funding partners.
Mitacs gratefully acknowledges the Government of Canada, the Networks of Centres of Excellence's Industrial Research and Development Internship program, Western Economic Diversification, the Atlantic Canada Opportunities Agency, Alberta Innovates Technology Futures and the governments of British Columbia, New Brunswick, Nova Scotia, Ontario, Quebec through Le Fonds de recherche du Québec - Nature et technologies, Manitoba, Saskatchewan and Newfoundland and Labrador through its Research and Development Corporation for their support of Mitacs Accelerate.
Mitacs gratefully acknowledges the Government of Canada, the Networks of Centres of Excellence's Industrial Research and Development Internship program, Western Economic Diversification, the Atlantic Canada Opportunities Agency, Alberta Innovates Technology Futures and the governments of British Columbia, New Brunswick, Nova Scotia, Ontario, Quebec through Le Fonds de recherche du Québec - Nature et technologies, Manitoba, Saskatchewan and Newfoundland and Labrador through its Research and Development Corporation for their support of Mitacs Accelerate.
When Actavis Specialty Pharmaceuticals Co. developed a new drug to treat uterine fibroids — benign tumors in a woman’s uterus — it partnered with Accelerate intern Bernice Tsoi to help create an economic model of the product. As a Health Research Methodology PhD student at McMaster University, conducting a thorough analysis of the drug’s costs and benefits was right up Bernice’s alley.
Chelation Partners’ approach to fighting antibiotic-resistant diseases is a novel one: cutting off their supply of iron. Without iron, bacteria have a tough time growing, and they’re more vulnerable to the effects of antibiotics. What’s more, Chelation Partners has discovered this tactic could also be applied to the fight against cancer. Cancer cells seem to be more sensitive to lower iron levels than other cells in the body, so reducing the availability of the metal might restrict the growth of cancer and boost the effectiveness of chemotherapy and radiation treatment.
